# China Pharma Holdings, Inc.: Form 10-K/A for the period ended Dec 31, 2007

- Company: [China Pharma Holdings, Inc.](/companies/cphi.md) (CIK 1106644)
- Form: 10-K/A
- Filed: 2009-06-24
- Accepted by EDGAR: Jun 24, 2009, 16:07 ET
- Period: 2007-12-31
- Accession: 0001010549-09-000449
- Inline XBRL: no
- Main document: https://www.sec.gov/Archives/edgar/data/1106644/000101054909000449/cph10ka123107.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1106644/000101054909000449/

## Controls and procedures

As filed, 7,597 characters.

### Disclosure Control and Procedures

We maintain disclosure controls and procedures designed to ensure that information required to be disclosed in our filings under the Securities Exchange Act of 1934 is (1) recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms and (2) accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

As required by Rule 13a-15 under the Exchange Act, as of the end of the fiscal year covered by this Annual Report on Form 10-K, we have carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures. This evaluation was carried out under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at December 31, 2007.

There have been no changes in our internal controls over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the fourth quarter of fiscal 2007 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

### Management's Report on Internal Control over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act.

Our management under the supervision of the Chief Executive Officer and the Chief Financial Officer has conducted an evaluation of our internal control over financial reporting as of December 31, 2007. In making its assessment, management used the criteria described in Internal Control Integrated Framework, issued by the Committee of Sponsoring Organizations of the Treadway Commission, or COSO. Based on our evaluation under the framework in Internal Control Integrated Framework, management concluded that our internal control over financial reporting was not effective as of December 31, 2007.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation.

A significant deficiency is a deficiency, or a combination of deficiencies, in internal control over financial reporting that is less severe than a material weakness, yet important enough to merit attention by those responsible for oversight of the company's financial reporting. The following significant deficiencies have been identified and included in our management's assessment as of December 31, 2007:

1\) We did not engage an Audit Committee to oversee the effectiveness of the system of internal control in every process. An effective Board of Directors and Audit Committee and other corporate governance functions will play an extremely important oversight role in the internal control system. If there is no Audit Committee or the Audit Committee does not function comprehensively and proactively, there might be reasonable possibility that the significant internal control deficiencies cannot be detected or prevented.

2\) We did not maintain effective controls internal audit function due to the lack of qualified internal auditors who are familiar with internal audit and US GAAP, and we did not implement adequate and proper supervisory review to ensure that the significant internal control deficiencies can be detected or prevented.

3\) We did not maintain effective controls over the financial reporting processes due to an insufficient complement of internal personnel with a level of accounting knowledge, experience and training in the application of U.S. GAAP commensurate with our financial requirements. For example, we did not maintain effective controls over accounting for deferred taxes under U.S. GAAP.

Our management believes that these internal control deficiencies result in a material weakness. This material weakness had not been fully remedied by December 31, 2007. Never the less, based upon a number of factors, including our plan for remediation (as described below) and other procedures designed to assist us in ensuring the reliability of our financial statements, our management believes that the consolidated financial statements included in the Annual Report on Form 10-KSB fairly state, in all material respects, our financial condition, results of operations and cash flows for the periods presented in conformity with generally accepted accounting principles in the

United States of America.

To remediate the significant internal control deficiencies described above in "Management's Report on Internal Control over Financial Reporting", we have implemented or plan to implement the measures described below, and will continue to evaluate and may in the future implement additional measures.

We have planned remediation measures of hiring and training of personnel which are intended to generally address these significant deficiencies by ensuring that we will have sufficient personnel with knowledge, experience and training in the application of U.S. GAAP commensurate with our financial reporting requirements. These measures include the following:

1\) We appointed 3 independent directors, on February 1, 2008, to establish an effective Audit Committee, together with setting up the relevant procedures and working plans;

2\) We will continue to hire external U.S. accountant at the beginning of 2008 with relevant accounting experience, skills and knowledge in the preparation of financial statements under the requirements of U.S. GAAP and financial reporting disclosure under the requirement of SEC rules; We also plan to train up our staff internally;

3\) We plan to hire an internal auditor to implement the internal audit function, and plan to train our accounting personnel in the application of U.S. GAAP commensurate with our financial reporting requirements;

4\) We plan to improve our written policies and procedures, as well as amend and supplement the existing code of conduct to ensure the compliance with Section 406 of Sarbanes-Oxley Act; and

5\) We retained and intend to continue to retain the services of outside counselors to advise us on the SEC disclosure requirements.

We believe that we are taking the steps necessary for remediation of the significant deficiencies identified above, and we will continue to monitor the effectiveness of these steps and to make any changes that our management deems appropriate.

The management’s assessment of internal controls over financial reporting was not subject to auditor attestation as of December, 31 2007 pursuant to temporary rules of the Securities and Exchange Commission. Accordingly, this Annual Report does not include an attestation report by our independent registered public accounting firm regarding internal control over financial reporting.

### Changes in Internal Controls over Financial Reporting

There were no changes in our internal controls over financial reporting during the fourth quarter of fiscal 2007 that have materially affected, or are reasonably likely to materially affect our internal control over financial reporting.

### art IV

Filed Jun 24, 2009.
Source: SEC EDGAR, the filing index for accession 0001010549-09-000449. Last ingested by Listed: Nov 11, 2026, 00:23 ET. No prices; not investment advice.
